-
Product Insights
NewNet Present Value Model: Candel Therapeutics Inc’s ProstAtak
Empower your strategies with our Net Present Value Model: Candel Therapeutics Inc's ProstAtak report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Novartis AG’s Iscalimab
Empower your strategies with our Net Present Value Model: Novartis AG's Iscalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAN-3110 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAN-3110 in High-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAN-3110 in High-Grade Glioma Drug Details: RQNestin-34.5v.2 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAN-3110 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAN-3110 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAN-3110 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: RQNestin-34.5v.2 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemigatinib in Astrocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemigatinib in Astrocytoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemigatinib in Astrocytoma Drug Details: Pemigatinib (Pemazyre) is acts as an anti neoplastic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Prostate Cancer Drug Details: aglatimagene besadenovec is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma Drug Details: aglatimagene besadenovec...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in High-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in High-Grade Glioma Drug Details: aglatimagene besadenovec is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Recurrent Malignant Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Malignant Glioma - Drugs In Development, 2023’, provides an overview of the Recurrent Malignant Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,...